Evidence map›Paper›PMID 41278157›Full record

ArticleWorld journal of gastroenterology2025

Early

Li Lin, Peng Zhang, Ya-Yue Wang, Yi-Fan Cai, Li-Bing Wen, Wei-Ping Chen, Yi-Fan Xiao, Zhi-Kun Li, Guo-Yan Liu

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Li LinDepartment of Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361102, Fujian Province, China.
Peng ZhangSchool of Clinical Medicine, Fujian Medical University, Fuzhou 350122, Fujian Province, China.
Ya-Yue WangSchool of Medicine, Xiamen University, Xiamen 361001, Fujian Province, China.
Yi-Fan CaiSchool of Medicine, Xiamen University, Xiamen 361001, Fujian Province, China.
Li-Bing WenSchool of Clinical Medicine, Fujian Medical University, Fuzhou 350122, Fujian Province, China.
Wei-Ping ChenSchool of Clinical Medicine, Fujian Medical University, Fuzhou 350122, Fujian Province, China.
Yi-Fan XiaoSchool of Medicine, Xiamen University, Xiamen 361001, Fujian Province, China.
Zhi-Kun LiSchool of Medicine, Xiamen University, Xiamen 361001, Fujian Province, China.
Guo-Yan LiuDepartment of Gastrointestinal Surgery, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361102, Fujian Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite emerging evidence from studies on other malignancies that support early adjuvant chemotherapy (AC) initiation, the feasibility and oncologic benefits of this therapy remain underexplored in patients receiving gastric resection.

aimTo evaluate the feasibility, safety, and oncologic outcomes of early postoperative AC in advanced gastric cancer patients.

methodsIn this retrospective cohort study, 219 stage II/III gastric adenocarcinoma patients who underwent laparoscopic gastrectomy between 2016 and 2021 were analyzed. Patients were stratified by AC initiation timing: Early (10-13 days,

resultsAfter 1:2 matching (21 patients

conclusionEarly AC initiation appears feasible in selected patients but necessitates individualized dose management. Our findings challenge traditional timing paradigms while highlighting the need for molecularly guided treatment sequencing strategies.

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsGastrectomyNeoplasm Recurrence, LocalStomach NeoplasmsAdultAgedChemotherapy, AdjuvantDisease-Free SurvivalFeasibility StudiesFemaleHumansLaparoscopyMaleMiddle AgedNeoplasm StagingAdjuvant chemotherapyGastric cancerPostoperative timingPropensity scoreRecurrence patternSurvival rate

Identifiers

PMID41278157
PMCPMC12635754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.